Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 166 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR What to Know About Using Activated Charcoal During Cancer December 21, 2023 COVID-19: “We’ve got so much on our plates” August 4, 2020 How Your Primary Care Provider Can Help You Throughout Your Cancer... March 5, 2021 FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer August 11, 2023 Load more HOT NEWS Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... Five Questions With…Jae. Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... New Approach Uses Much Less Tissue to Analyze Tumor Proteins and...
